Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6

Ibrutinib may inhibit intestinal CYP3A4 and induce CYP2B6 and/or CYP3A. Secondary to potential induction, ibrutinib may reduce the exposure and effectiveness of oral contraceptives (OCs). This phase I study evaluated the effect of ibrutinib on the pharmacokinetics of the CYP2B6 substrate bupropion,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pharmacol Res Perspect
Main Authors: de Jong, Jan, Mitselos, Anna, Jurczak, Wojciech, Cordoba, Raul, Panizo, Carlos, Wrobel, Tomasz, Dlugosz‐Danecka, Monika, Jiao, James, Sukbuntherng, Juthamas, Ouellet, Daniele, Hellemans, Peter
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7506988/
https://ncbi.nlm.nih.gov/pubmed/32945596
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.649
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados